Literature DB >> 27915168

Interactions of long-chain homologues of colchicine with tubulin.

Ana Marzo-Mas1, Pascale Barbier2, Gilles Breuzard2, Diane Allegro2, Eva Falomir1, Juan Murga3, Miguel Carda1, Vincent Peyrot4, J Alberto Marco5.   

Abstract

Several colchicine analogues in which the N-acetyl residue has been replaced by aliphatic, straight-chain acyl moieties, have been synthesized. These compounds show high cytotoxic activity at the nanomolar level against the tumoral cell lines HT-29, MCF-7 and A549. Some of them exhibit activities in the picomolar range against the HT-29 line and are thus two to three orders of magnitude more cytotoxic than colchicine. In this specific cell line, the activities were found to be closely related to the length of the acyl carbon chain, an increase in the latter giving rise to an increase in the cytotoxicity with a maximum in the range of 10-12 carbon atoms, followed by a decrease in activity with still longer chains. Some of the compounds inhibit microtubule assembly and induce the formation of abnormal polymers and present in most cases better apparent affinity constants than colchicine. In addition, at IC50 concentrations the analogues block the cell cycle of A549 cells in the G2/M phase. Molecular docking studies suggest that, while interactions of the colchicine analogues with the colchicine binding site at β-tubulin are still present, the increase in the acyl chain length leads to the progressive development of new interactions, not present in colchicine itself, with the neighboring α-tubulin subunit. Indeed, sufficiently long acyl chains span the intradimer interface and contact with a hydrophobic groove in α-tubulin. It is worth noting that some of the compounds show cytotoxicity at concentrations three orders of magnitude lower than colchicine. Their pharmacological use in cancer therapy could possibly be performed with lower dosages and be thus endowed with less acute toxicity problems than in the case of colchicine.
Copyright © 2016 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Abnormal polymerization; Colchicine; Cytotoxicity; Docking studies; Microtubules; Tubulin

Mesh:

Substances:

Year:  2016        PMID: 27915168     DOI: 10.1016/j.ejmech.2016.11.049

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  5 in total

1.  Synthesis of Combretastatin A-4 and 3'-Aminocombretastatin A-4 derivatives with Aminoacid Containing Pendants and Study of Their Interaction with Tubulin and as Downregulators of the VEGF, hTERT and c-Myc Gene Expression.

Authors:  Raül Agut; Eva Falomir; Juan Murga; Celia Martín-Beltrán; Raquel Gil-Edo; Alberto Pla; Miguel Carda; J Alberto Marco
Journal:  Molecules       Date:  2020-02-04       Impact factor: 4.411

2.  Antiproliferative Activity and Molecular Docking of Novel Double-Modified Colchicine Derivatives.

Authors:  Urszula Majcher; Greta Klejborowska; Mahshad Moshari; Ewa Maj; Joanna Wietrzyk; Franz Bartl; Jack A Tuszynski; Adam Huczyński
Journal:  Cells       Date:  2018-11-01       Impact factor: 6.600

3.  Synthesis and Antiproliferative Screening Of Novel Analogs of Regioselectively Demethylated Colchicine and Thiocolchicine.

Authors:  Dominika Czerwonka; Szymon Sobczak; Ewa Maj; Joanna Wietrzyk; Andrzej Katrusiak; Adam Huczyński
Journal:  Molecules       Date:  2020-03-05       Impact factor: 4.411

4.  New Series of Double-Modified Colchicine Derivatives: Synthesis, Cytotoxic Effect and Molecular Docking.

Authors:  Julia Krzywik; Maral Aminpour; Ewa Maj; Witold Mozga; Joanna Wietrzyk; Jack A Tuszyński; Adam Huczyński
Journal:  Molecules       Date:  2020-08-02       Impact factor: 4.411

5.  Bioinformatic analysis revealing mitotic spindle assembly regulated NDC80 and MAD2L1 as prognostic biomarkers in non-small cell lung cancer development.

Authors:  Rong Wei; Ziyue Wang; Yaping Zhang; Bin Wang; Ningning Shen; Li E; Xin Li; Lifang Shang; Yangwei Shang; Wenpeng Yan; Xiaoqin Zhang; Wenxia Ma; Chen Wang
Journal:  BMC Med Genomics       Date:  2020-08-14       Impact factor: 3.063

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.